AstraZeneca has been removed from Denmark’s COVID-19 vaccine program, and this was officially announced on Wednesday, April 14. With this decision, the region became the first country to completely abandon this brand of coronavirus shots.
Delayed vaccination schedule
As per Reuters, the move will put off Denmark’s scheduled completion of its AstraZeneca vaccination scheme that was initially set to July 25. The new date has been moved to early August, according to health authorities.
This means that everyone who already has vaccination appointments for AstraZeneca vaccine shots will be canceled and rescheduled. For those who have received the first dose, they will not be getting the pulled-out vaccine anymore, but a new brand will be administered as a second dose.
It was added that those who are 16 years old and above could expect to get an offer for vaccination in late June. The individuals who will accept the offer will be inoculated five weeks later, which is in early August.
Why Denmark ditches AstraZeneca
The Danish Health Authority released a statement and cited rare side effects and others as reasons for the decision to stop administering the AstraZeneca vaccine to the citizens. The agency further explained that while the benefits o- taking the shots outweigh the risks, they still chose to discontinue due to the possible link to rare cases of blood clotting. The health authority added that other vaccines are also available in Denmark, so they could just use this.
"Based on the scientific findings, our overall assessment is there is a real risk of severe side effects associated with using the COVID-19 vaccine from AstraZeneca," DHA’s director-general, Søren Brostrøm, said. "We have, therefore, decided to remove the vaccine from our vaccination program."
He went on to explained, "In the midst of an epidemic, it has been a difficult decision to continue our vaccination program without an effective and readily available vaccine against COVID-19. However, we have other vaccines at our disposal, and the epidemic is currently under control.
Once the administration of COVID-19 vaccines starts again in Denmark, it was said that the Johnson & Johnson brand would be used. In any case, this vaccine was rolled out in Europe and got delayed due to reports of the same blood clotting that was said to have developed in some people who had the AstraZeneca vaccine.


Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
Yen Stabilizes Near Lows as Japan Signals Readiness to Intervene Amid Dollar Weakness
Japan Revises Economic Growth Forecast as Stimulus Fuels Consumption and Investment
Global Markets Rise as Tech Stocks Lead, Yen Strengthens, and Commodities Hit Record Highs
Russian Stocks End Lower as Energy and Mining Shares Weigh on MOEX Index
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Tokyo Core Inflation Stays Above BOJ Target, Strengthening Case for Further Rate Hikes
Italy Fines Apple €98.6 Million Over App Store Dominance
Gold Prices Surge to Record Highs as Geopolitical Tensions Fuel Safe-Haven Demand
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
Taiwan Stock Market Ends Higher as Semiconductor and Energy Shares Lead Gains
U.S. Stock Index Futures Steady After S&P 500 Hits Record on Strong Economic Data
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Platinum Price Surges Past $2,000 as Demand and Supply Dynamics Tighten 



